Drug Profile
Research programme: vanadium compounds - Angiotech
Latest Information Update: 16 Nov 2006
Price :
$50
*
At a glance
- Originator Angiotech Pharmaceuticals
- Class
- Mechanism of Action Angiogenesis inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Rheumatoid arthritis
Most Recent Events
- 14 Aug 2001 No-Development-Reported for Cancer in Canada (Unknown route)
- 14 Aug 2001 No-Development-Reported for Rheumatoid arthritis in Canada (Unknown route)
- 22 Jun 1998 Preclinical development for Cancer in Canada (Unknown route)